245 related articles for article (PubMed ID: 19269014)
1. HER-2 amplification is highly homogenous in gastric cancer.
Marx AH; Tharun L; Muth J; Dancau AM; Simon R; Yekebas E; Kaifi JT; Mirlacher M; Brümmendorf TH; Bokemeyer C; Izbicki JR; Sauter G
Hum Pathol; 2009 Jun; 40(6):769-77. PubMed ID: 19269014
[TBL] [Abstract][Full Text] [Related]
2. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.
Marx AH; Burandt EC; Choschzick M; Simon R; Yekebas E; Kaifi JT; Mirlacher M; Atanackovic D; Bokemeyer C; Fiedler W; Terracciano L; Sauter G; Izbicki JR
Hum Pathol; 2010 Nov; 41(11):1577-85. PubMed ID: 20656317
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
[TBL] [Abstract][Full Text] [Related]
5. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.
Tanner M; Hollmén M; Junttila TT; Kapanen AI; Tommola S; Soini Y; Helin H; Salo J; Joensuu H; Sihvo E; Elenius K; Isola J
Ann Oncol; 2005 Feb; 16(2):273-8. PubMed ID: 15668283
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
7. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
8. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
Tanner M; Järvinen P; Isola J
Cancer Res; 2001 Jul; 61(14):5345-8. PubMed ID: 11454672
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
11. HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis.
Negri FV; Bozzetti C; Ardizzoni A; Lagrasta C; Crafa P; Silini EM
Hum Pathol; 2011 Jun; 42(6):909-10; author reply 910-1. PubMed ID: 21571126
[No Abstract] [Full Text] [Related]
12. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers.
Bizari L; Borim AA; Leite KR; Gonçalves Fde T; Cury PM; Tajara EH; Silva AE
Cancer Genet Cytogenet; 2006 Feb; 165(1):41-50. PubMed ID: 16490596
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
Järvinen TA; Liu ET
Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
[TBL] [Abstract][Full Text] [Related]
14. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization.
Tajiri R; Ooi A; Fujimura T; Dobashi Y; Oyama T; Nakamura R; Ikeda H
Hum Pathol; 2014 Apr; 45(4):725-34. PubMed ID: 24491355
[TBL] [Abstract][Full Text] [Related]
16. ERBB2 amplifications in esophageal adenocarcinoma.
Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab in gastric cancer.
Okines AF; Cunningham D
Eur J Cancer; 2010 Jul; 46(11):1949-59. PubMed ID: 20542421
[TBL] [Abstract][Full Text] [Related]
18. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
Liu W; Zhong S; Chen J; Yu Y
J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
[TBL] [Abstract][Full Text] [Related]
20. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]